

diabetes

A JOURNAL OF
THE AMERICAN
DIABETES
ASSOCIATION®

The effect of immediate polyethylene glycol precipitation on free insulin measurements in diabetic patients with insulin antibodies R. RUDKOWSKI AND G. ANTONY	253
Insulin induces progressive insulin resistance in cultured rat adipocytes: sequential effects at receptor and multiple postreceptor sites W. T. GARVEY, J. M. OLEFSKY, AND S. MARSHALL	258
Putative hypothalamic glucoreceptors play no essential role in the response to moderate hypoglycemia P. CANE, R. ARTAL, AND R. N. BERGMAN	268
Triglyceride-lowering effect of dietary vitamin E in streptozocin-induced diabetic rats: increased lipoprotein lipase activity in livers of diabetic rats fed high dietary vitamin E K. A. PRITCHARD, JR., S. T. PATEL, C. W. KARPEN, H. A. I. NEWMAN, AND R. V. PANGANAMALA	278
Effects of obesity, hyperinsulinemia, and glucose intolerance on insulin action in adipose tissue of sixty-year-old men J. BOLINDER, H. LITHELL, E. SKARFORS, AND P. ARNER	282
Aldehyde dehydrogenase activity and large vessel disease in diabetes mellitus: a preliminary study P. JERNTORP, H. ÖHLIN, AND L.-O. ALMÉR	291
Prevention of basement membrane thickening in retinal capillaries by a novel inhibitor of aldose reductase, tolrestat W. G. ROBISON, JR., P. F. KADOR, Y. AKAGI, J. H. KINOSHITA, R. GONZALEZ, AND D. DVORNIK	295
Islet cell proteins defined by monoclonal islet cell antibody HISL-19 S. SRIKANTA, K. KRISCH, AND G. S. EISENBARTH	300
Hepatic glycogen metabolism and insulin receptor status after long-term peripheral insulin delivery in the islet-transplanted diabetic rat Y. T. KRUSZYNSKA, P. D. HOME, L. AGIUS, AND K. G. M. M. ALBERTI	306
In vivo deactivation of proinsulin action on glucose disposal and hepatic glucose production in normal man H. S. GLAUBER, R. R. REVERS, R. HENRY, L. SCHMEISER, P. WALLACE, O. G. KOLTERMAN, R. M. COHEN, A. H. RUBENSTEIN, J. A. GALLOWAY, B. F. FRANK, AND J. M. OLEFSKY	311
Kinetics of biosynthetic human proinsulin action in isolated rat adipocytes T. P. CIARALDI, D. BRADY, AND J. M. OLEFSKY	318
Reduction by morphine of human postprandial insulin release is secondary to inhibition of gastrointestinal motility S. N. SULLIVAN, M. G. LEE, S. R. BLOOM, L. LAMKI, AND J. DUPRÉ	324
Cold exposure reverses the diabetogenic effects of high-fat feeding A. L. VALLERAND, J. LUPIEN, AND L. J. BUKOWIECKI	329
The prevalence of islet cell antibodies in Japanese insulin-dependent and non-insulin-dependent diabetic patients studied by indirect immunofluorescence and by a new method T. KOBAYASHI, T. SUGIMOTO, T. ITOH, K. KOSAKA, T. TANAKA, S. SUWA, K. SATO, AND K. TSUJI	335
Renin secretion by the spontaneously diabetic rat A. J. COHEN, D. M. McCARTHY, AND R. R. ROSSETTI	341
Reversal of mesangial enlargement in rats with long-standing diabetes by whole pancreas transplantation M. J. ORLOFF, N. YAMANAKA, G. E. GREENLEAF, Y.-T. HUANG, D.-G. HUANG, AND X.-S. LENG	347
Mitogenic activity and receptor reactivity of hybrid molecules containing portions of the insulin-like growth factor I (IGF-I), IGF-II, and insulin molecules M. A. DE VROEDE, M. M. RECHLER, S. P. NISSLEY, H. OGAWA, S. JOSHI, G. T. BURKE, AND P. G. KATSOYANNIS	355
The insulin sensitivity index in nondiabetic man: correlation between clamp-derived and IVGTT-derived values J. C. BEARD, R. N. BERGMAN, W. K. WARD, AND D. PORTE, JR.	362
RAPID PUBLICATION	
The third phase of in vitro insulin secretion: evidence for glucose insensitivity J. L. BOLAFFI, A. HELDT, L. D. LEWIS, AND G. M. GRODSKY	370
ORGANIZATION SECTION	
REVIEWERS OF MANUSCRIPTS	376



When a type II diabetic patient needs more than diet, unique MICRONASE[®] Tablets (glyburide) are a logical first choice.

Choosing antidiabetic

1. Micronase—a rational choice in type II diabetes


Insulin levels are normal or elevated in most patients with type II diabetes, although insulin action is markedly impaired. MICRONASE helps normalize the tissue response to endogenous insulin.

Initially, MICRONASE helps lower serum glucose in responsive patients by stimulating the release of additional insulin. As therapy continues, MICRONASE is believed to promote peripheral glucose metabolism by helping to correct defects at the cellular receptor and postreceptor levels.



2. Micronase—a single, daily dose provides 24-hour glycemic control

MICRONASE provides 24-hour control of blood glucose with a single, daily, low-milligram dose. MICRONASE may be taken with food, since food intake does not appear to affect its bioavailability.



3. Micronase—for the type II diabetic patient who is also hypertensive: Control without risk of water retention

This may also be significant for the type II diabetic patient with congestive heart failure. MICRONASE actually causes a mild diuresis.

therapy today

4. Micronase—an important consideration in the type II diabetic patient with renal impairment: Control plus unique dual excretion... 50% urine, 50% bile


Elimination of MICRONASE equally in bile and urine reduces the risk of drug accumulation, which may result in hypoglycemia. MICRONASE should be used with caution in patients with renal impairment; however, in a single-dose study, plasma clearance of MICRONASE was prolonged only in patients with severe renal impairment.

5. Micronase—for the patient who fails on other diabetic therapy: Potency and dosage flexibility

MICRONASE may prove effective when other drugs fail. Five mg of MICRONASE is approximately equivalent to 250 mg of chlorpropamide or 500 mg of acetohexamide in its ability to lower blood glucose. The dosage range of MICRONASE allows for greater dosage flexibility than other agents.

Overdosage of sulfonylureas, including MICRONASE, can cause hypoglycemia. Although the interpretations are controversial, the UGDP study reported in 1970 that the use of tolbutamide, an oral hypoglycemic drug, was associated with increased cardiovascular mortality.

Upjohn The Upjohn Company
Kalamazoo, MI 49001



Your initial Rx in type II diabetes

Micronase[®]
glyburide, **5 mg** Tablets

For brief summary of prescribing information, please turn page.

Micronase® An advance in diabetes management

Dosage Guide*

Although relatively rare, hypoglycemia may occur during the conversion to MICRONASE from other therapy

Prior therapy or condition	Considerations before starting therapy	Initial MICRONASE dose (mg/day)
Dietary therapy ineffective	No priming necessary	1.25 to 5.0 mg
Oral therapy	Discontinue oral hypoglycemic*	2.5 to 5.0 mg
Insulin therapy (< 40 units/day)	Completely discontinue insulin injections under medical supervision	2.5 to 5.0 mg
Insulin therapy (> 40 units/day)	Gradually discontinue insulin injections under close medical observation or hospitalization	5.0 mg

*See complete prescribing information.

*See package insert for special precautions when transferring patients from chlorpropamide.

Micronase Tablets (brand of glyburide tablets)

INDICATIONS AND USAGE MICRONASE Tablets are indicated as an adjunct to diet to lower the blood glucose in patients with non-insulin-dependent diabetes mellitus (type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.

CONTRAINDICATIONS MICRONASE Tablets are contraindicated in patients with: 1. Known hypersensitivity or allergy to the drug. 2. Diabetic ketoacidosis, with or without coma. This condition should be treated with insulin. 3. Type I diabetes mellitus, as sole therapy.

SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY. The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups (*Diabetes*, 19 (Suppl 2):747-830, 1970).

UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2½ times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and advantages of MICRONASE and of alternative modes of therapy.

Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure.

PRECAUTIONS *General Hypoglycemia:* All sulfonylureas are capable of producing severe hypoglycemia. Proper patient selection and dosage and instructions are important to avoid hypoglycemic episodes. Renal or hepatic insufficiency may increase the risk of serious hypoglycemic reactions. Elderly, debilitated or malnourished patients, and those with adrenal or pituitary insufficiency, are particularly susceptible to the hypoglycemic action of glucose-lowering drugs. Hypoglycemia may be difficult to recognize in the elderly and in people who are taking beta-adrenergic blocking drugs. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when alcohol is ingested, or when more than one glucose lowering drug is used.

Loss of Control of Blood Glucose: In diabetic patients exposed to stress such as fever, trauma, infection or surgery, a loss of control may occur. It may then be necessary to discontinue MICRONASE and administer insulin. Adequate adjustment of dose and adherence to diet should be assessed before classifying a patient as a secondary failure.

Information for Patients: Patients should be informed of the potential risks and advantages of MICRONASE and of alternative modes of therapy. They also should be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of urine and/or blood glucose. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members. Primary and secondary failure should also be explained. **Laboratory Tests** Response to MICRONASE Tablets should be monitored by frequent urine glucose tests and periodic blood glucose tests. Measurement of glycosylated hemoglobin levels may be helpful in some patients. **Drug Interactions** The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. **Carcinogenesis, Mutagenesis, and Impairment of Fertility** Studies in rats at doses up to 300 mg/kg/day for 18 months showed no carcinogenic effects. Glyburide is nonmutagenic when studied in the Salmonella microsome test (Ames test) and in the DNA damage/alkaline elution assay.

Pregnancy Teratogenic Effects: Pregnancy Category B. Reproduction studies in rats and rabbits have revealed no evidence of impaired fertility or harm to the fetus due to glyburide. There are no adequate and well controlled studies in pregnant women. This drug should be used during pregnancy only if clearly needed. Insulin should be used during pregnancy to maintain blood glucose as close to normal as possible.

Nonteratogenic Effects: Prolonged severe hypoglycemia (4 to 10 days) has been reported in neonates born to mothers who were receiving a sulfonylurea drug at the time of delivery. MICRONASE should be discontinued at least two weeks before the expected delivery date. **Nursing Mothers** Some sulfonylurea drugs are known to be excreted in human milk. Insulin therapy should be considered. **Pediatric Use** Safety and effectiveness in children have not been established.

ADVERSE REACTIONS **Hypoglycemia:** See Precautions and Overdosage sections. **Gastrointestinal Reactions:** Cholestatic jaundice may occur rarely; MICRONASE Tablets should be discontinued if this occurs. Gastrointestinal disturbances, e.g., nausea, epigastric fullness, and heartburn are the most common reactions, having occurred in 1.8% of treated patients during clinical trials. They tend to be dose related and may disappear when dosage is reduced. **Dermatologic Reactions:** Allergic skin reactions, e.g., pruritis, erythema, urticaria, and morbilliform or maculopapular eruptions occurred in 1.5% of treated patients during clinical trials. These may be transient and may disappear despite continued use of MICRONASE; if skin reactions persist, the drug should be discontinued. **Porphyria cutanea tarda** and photosensitivity reactions have been reported with sulfonylureas. **Hematologic Reactions:** Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, aplastic anemia, and pancytopenia have been reported with sulfonylureas.

Metabolic Reactions: Hepatic porphyria and disulfiram-like reactions have been reported with sulfonylureas; however, hepatic porphyria has not been reported with MICRONASE and disulfiram-like reactions have been reported very rarely.

OVERDOSAGE Overdosage of sulfonylureas, including MICRONASE Tablets, can produce hypoglycemia. If hypoglycemic coma is diagnosed or suspected, the patient should be given a rapid intravenous injection of concentrated (50%) glucose solution. This should be followed by a continuous infusion of a more dilute (10%) glucose solution at a rate which will maintain the blood glucose at a level above 100 mg/dL. Patients should be closely monitored for a minimum of 24 to 48 hours, since hypoglycemia may recur after apparent clinical recovery.

DOSAGE AND ADMINISTRATION There is no fixed dosage regimen for the management of diabetes mellitus with MICRONASE Tablets. **Usual Starting Dose** The usual starting dose is 2.5 to 5.0 mg daily, administered with breakfast or the first main meal. Those patients who may be more sensitive to hypoglycemic drugs should be started at 1.25 mg daily. (See Precautions Section for patients at increased risk.) **Maximum Dose** Daily doses of more than 20 mg are not recommended. **Dosage Interval** Once-a-day therapy is usually satisfactory. Some patients, particularly those receiving more than 10 mg daily, may have a more satisfactory response with twice-a-day dosage.

Caution: Federal law prohibits dispensing without prescription.
For additional product information see your Upjohn representative.

Upjohn

B-2-S J-5453 May 1985 The Upjohn Company, Kalamazoo, MI 49001, USA

MARCH AUTHOR INDEX

(Volume 35, Number 3)

- | | |
|---------------------------|-------------------------------|
| Agius, L., 306 | Kolterman, O. G., 311 |
| Akagi, Y., 295 | Kosaka, K., 335 |
| Alberti, K. G. M. M., 306 | Krisch, K., 300 |
| Almer, L.-O., 291 | Kruszynska, Y. T., 306 |
| Antony, G., 253 | |
| Arner, P., 282 | Lamki, L., 324 |
| Artal, R., 268 | Lee, M. G., 324 |
| | Leng, X.-S., 347 |
| Beard, J. C., 362 | Lewis, L. D., 370 |
| Bergman, R. N., 268, 362 | Lithell, H., 282 |
| Bloom, S. R., 324 | Lupien, J., 329 |
| Bolaffi, J. L., 370 | |
| Bolinder, J., 282 | Marshall, S., 258 |
| Brady, D., 318 | McCarthy, D. M., 341 |
| Bukowiecki, L. J., 329 | |
| Burke, G. T., 355 | Newman, H. A. I., 278 |
| | Nissley, S. P., 355 |
| Cane, P., 268 | |
| Ciaraldi, T. P., 318 | Ogawa, H., 355 |
| Cohen, A. J., 341 | Öhlin, H., 291 |
| Cohen, R. M., 311 | Olefsky, J. M., 258, 311, 318 |
| | Orloff, M. J., 347 |
| De Vroede, M. A., 355 | |
| Dupré, J., 324 | Panganamala, R. V., 278 |
| Dvornik, D., 295 | Patel, S. T., 278 |
| | Porte, D., Jr., 362 |
| Eisenbarth, G. S., 300 | Pritchard, K. A., Jr., 278 |
| | |
| Frank, B. F., 311 | |
| | Rechler, M. M., 355 |
| Galloway, J. A., 311 | Revers, R. R., 311 |
| Garvey, W. T., 258 | Robison, W. G., Jr., 295 |
| Glauber, H. S., 311 | Rossetti, R. R., 341 |
| Gonzalez, R., 295 | Rubenstein, A. H., 311 |
| Greenleaf, G. E., 347 | Rudkowski, R., 253 |
| Grodsky, G. M., 370 | |
| | Sato, K., 335 |
| Heldt, A., 370 | Schmeiser, L., 311 |
| Henry, R., 311 | Skarfors, E., 282 |
| Home, P. D., 306 | Srikanta, S., 300 |
| Huang, D.-G., 347 | Sugimoto, T., 335 |
| Huang, Y.-T., 347 | Sullivan, S. N., 324 |
| | Suwa, S., 335 |
| Itoh, T., 335 | |
| | Tanaka, T., 335 |
| Jerntorp, P., 291 | Tsuji, K., 335 |
| Joshi, S., 355 | |
| | Vallerand, A. L., 329 |
| Kador, P. F., 295 | |
| Karpen, C. W., 278 | Wallace, P., 311 |
| Katsoyannis, P. G., 355 | Ward, W. K., 362 |
| Kinoshita, J. H., 295 | |
| Kobayashi, T., 335 | Yamanaka, N., 347 |

Editor

CHARLES J. GOODNER, M.D.

Associate Editors

EDWIN L. BIERMAN, M.D.

JOHN W. ENSINCK, M.D.

WILFRED Y. FUJIMOTO, M.D.

JERRY P. PALMER, M.D.

EDITORIAL BOARD

CLYDE F. BARKER, M.D.

WILLIAM S. BRIMIJOIN, Ph.D.

H. FRANKLIN BUNN, M.D.

ALAN D. CHERRINGTON, Ph.D.

SAMUEL W. CUSHMAN, Ph.D.

JOSEPH M. DAVIE, M.D., Ph.D.

ROBERT P. ELDE, Ph.D.

GEROLD M. GRODSKY, M.D.

JEFFREY B. HALTER, M.D.

ABBAS E. KITABCHI, M.D.

ORVILLE G. KOLTERMAN, M.D.

TETSURO KONO, Ph.D.

AKE LERNMARK, M.D.

S. MICHAEL MAUER, M.D.

DANIEL H. MINTZ, M.D.

BARRY I. POSNER, M.D.

R. PAUL ROBERTSON, M.D.

ROBERT SHERWIN, M.D.

DONALD F. STEINER, M.D.

GEORGE STEINER, M.D.

MICHAEL P. STERN, M.D.

GORDON WEIR, M.D.

ROSALYN S. YALOW, Ph.D.

CECIL YIP, Ph.D.

Publisher

CAROLINE STEVENS

Director of Professional Publications

BEVERLY BRITTAN COOK

Managing Editor

ORIT LOWY

Assistant Editor

BEVERLY B. LAWRENCE

Editorial Assistant

AUGUSTA LITWER

Marketing Director

JADINE ZEMSKY

American Diabetes Association**Officers 1985-86****Chairman of the Board**

HENRY RIVERA

President

HAROLD RIFKIN, M.D.

Chairman of the Board-Elect

SAM GALLO

President-Elect

DANIEL PORTE, JR., M.D.

Vice-Chairman

DOUGLAS DODD

Vice-Presidents

JOHN COLWELL, M.D.

LINDA HURWITZ, R.N.

Secretary

FRANK ROSENHOOVER

Treasurer

NORMAN RICKEMAN

Past Chairman of the Board

JOSEPH DAVIS

Past President

KARL SUSSMAN, M.D.

Executive Vice-President

ROBERT S. BOLAN

diabetes

A JOURNAL OF THE AMERICAN DIABETES ASSOCIATION.

DIABETES is published by the American Diabetes Association, Inc., to provide an official Journal for the Association and to furnish the medical profession with information concerning diabetes and related fields of medicine.

The Journal does not publish material that has been reported elsewhere. In submitting an article the author(s) must state in the covering letter that the material has not been published elsewhere and has not been submitted for publication elsewhere. Prior publication specifically includes symposia, proceedings, preliminary communications, books, and invited articles. It is assumed that all human investigation shall have been conducted according to the principles expressed in the Declaration of Helsinki. Accepted manuscripts incur a charge of \$25 per printed page.

For studies involving experimental animals, state the species, strain, number used, and other pertinent descriptive characteristics. For human subjects or patients, describe their characteristics. When describing surgical procedures on animals, identify the preanesthetic and anesthetic agents used, and state the amount or concentration and the route and frequency of administration for each. The use of paralytic agents, such as curare or succinylcholine, is not an acceptable substitute for anesthetics. For other invasive procedures on animals, report the analgesic or tranquilizing drugs used; if none was used, provide justification for such exclusion. When reporting studies on unanesthetized animals or on humans, indicate that the procedures followed were in accordance with institutional guidelines.

In view of *The Copyright Revision Act of 1976*, all transmittal letters to the editor must contain the following language before manuscripts can be reviewed for possible publication: "In consideration of ADA's taking action in reviewing and editing my (our) submission, the author(s) undersigned hereby transfers, assigns, or otherwise conveys all copyright ownership to the ADA in the event that such work is published by the ADA. "We regret that transmittal letters not containing the foregoing language signed by all authors of the manuscript will necessitate return of your manuscript."

Matter appearing in DIABETES is copyrighted by the American Diabetes Association, Inc. Permission to reproduce all or parts of papers appearing in it may be granted under appropriate conditions and if proper credit is given. Such requests should be addressed in writing to the Permissions Editor, accompanied by a letter of permission from the senior author.

SUBSCRIPTION AND ADVERTISING

DIABETES: A Journal of the American Diabetes Association (ISSN 0012-1797) is published every month by the Association at the National Service Center, 1660 Duke Street, Alexandria, Virginia 22314. Copyright 1986 by the American Diabetes Association, Inc. All rights reserved under International and Pan-American Copyright Convention.

Second class postage paid at New York, NY, and additional mailing offices. POSTMASTER: Send address changes to DIABETES, American Diabetes Association, Inc., National Service Center, 1660 Duke Street, Alexandria, Virginia 22314.

Professional members receive the journal as part of their membership privileges. The annual subscription rates for nonmembers are as follows: \$60.00 for one year; \$108.00 for two years. Foreign postage at \$12.50 per year applies to all foreign coun-

All signed articles and editorials are the responsibility of the author(s) and not that of the American Diabetes Association. The Editors will be pleased to consider for publication papers presented at the Annual Meeting of the Association.

Rapid Publications: Observations considered to be of unusual importance may be submitted as a Rapid Publication. Editorial decision will be made within 10 days after receipt of the manuscript. No written review or explanation of the decision will be provided. Rejected papers may be resubmitted as a regular manuscript and reviewed accordingly. Rapid Publications may not exceed 10 double-spaced typewritten pages (including figures, tables, and references). Accepted papers will be published in the earliest possible issue of the Journal.

Manuscripts should be typewritten, with double spacing, and submitted in triplicate together with three copies of figures and photomicrographs. Manuscripts prepared in accord with the requirements specified in the document, "Uniform Requirements for Manuscripts Submitted to Biomedical Journals," *Annals of Internal Medicine* 1982; 96:766-71, will be considered for publication.

References should be presented in the style of the following examples and numbered in order of appearance in the text: For Periodicals—Banting, F. G., and Best, C. H.: The internal secretion of the pancreas. *J. Lab. Clin. Med.* 1922; 7:251-66. For Books—Allen, Frederick M.: *Studies Concerning Glycosuria and Diabetes*, Cambridge, Harvard University Press, 1913:461.

An abstract or summary of the content of the paper of not more than 250 words should be provided. This should be self-contained and understandable without reference to the text.

Photographs, drawings, and figures should be suitable for reproduction. Photographs should be unmounted, untrimmed glossy prints. The names of authors should appear on the back. The tops of photographs and figures should be indicated.


Galley proofs are sent to the principal author with a price list and order blank for reprints.

All manuscripts and related correspondence should be addressed to Charles J. Goodner, M.D., Harborview Medical Center, 325 Ninth Avenue, Seattle, WA 98104. Editorial correspondence should be addressed to the Editorial Office, DIABETES, American Diabetes Association, Inc., National Service Center, 1660 Duke Street, Alexandria, Virginia 22314.

tries, including Canada, Mexico, and other countries in the Postal Union of the Americas and Spain. Individual copies \$7.00.

Correspondence concerning subscriptions should be addressed to Subscription Department, DIABETES. Checks, money orders, and drafts for subscriptions should be made payable to the American Diabetes Association, Inc., and sent to the aforementioned address.

All inquiries about advertising should be addressed to the advertising traffic coordinator at Pharmaceutical Media, Inc., 130 Madison Avenue, New York, NY 10016, ATTENTION: Mary L. Cook. Tel: (212) 685-5010. The publishers reserve in their full discretion the right to accept or reject any proposed advertisement and the right to cancel any advertising contract.



**In Type II*
Diabetes:**

**When persistent hyperglycemia
or adverse effects signal the need
for a change—**


*Non-insulin-Dependent Diabetes Mellitus (NIDDM)

Although the findings are controversial, the UGDP study reported in 1970 that the use of tolbutamide, an oral sulfonylurea, was associated with increased cardiovascular risk.

R_x

Diabeta.[®]
(glyburide)
2.5mg q 24h
c Breakfast or
first main meal
Sig. # 30

Dispense as written



Consider
the world's
most prescribed
oral hypoglycemic
agent:

**Data on file, Hoechst-Roussel Pharmaceuticals Inc.

See following page for brief summary of prescribing information.

Hoechst-Roussel Pharmaceuticals Inc.
Somerville, New Jersey 08876

Hoechst 

Control: High success rate**
(77%-100%) reported in Type II
diabetics who fail on diet alone.

Effective in some patients who fail on
other oral agents.

Compliance: Simple one-a-day
dosage regimen for most patients.
Low incidence of side effects.

Confidence: Safety proven in over
15 years of clinical use.

DIET &

Diabeta[®] TABLETS
1.25, 2.5
and 5mg
(GLYBURIDE)

THE WORLD'S MOST PRESCRIBED ORAL HYPOGLYCEMIC AGENT

DiaBeta® (glyburide) Tablets 1.25, 2.5 and 5 mg

BRIEF SUMMARY

INDICATIONS AND USAGE

DiaBeta® (glyburide) is indicated as an adjunct to diet to lower the blood glucose in patients with non-insulin-dependent diabetes mellitus (Type II) whose hyperglycemia cannot be controlled by diet alone.

In initiating treatment for non-insulin-dependent diabetes, diet should be emphasized as the primary form of treatment. Caloric restriction and weight loss are essential in the obese diabetic patient. Proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycemia. The importance of regular physical activity should also be stressed, and cardiovascular risk factors should be identified and corrective measures taken where possible.

If this treatment program fails to reduce symptoms and/or blood glucose, the use of an oral sulfonylurea or insulin should be considered. Use of DiaBeta® (glyburide) must be viewed by both the physician and patient as a treatment in addition to diet, and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint. Furthermore, loss of blood glucose control on diet alone may be transient, thus requiring only short-term administration of DiaBeta® (glyburide).

During maintenance programs, DiaBeta® (glyburide) should be discontinued if satisfactory lowering of blood glucose is no longer achieved. Judgments should be based on regular clinical and laboratory evaluations.

In considering the use of DiaBeta® (glyburide) in asymptomatic patients, it should be recognized that controlling the blood glucose in non-insulin-dependent diabetes has not been definitely established to be effective in preventing the long-term cardiovascular or neural complications of diabetes.

CONTRAINDICATIONS

DiaBeta® (glyburide) is contraindicated in patients with:

1. Known hypersensitivity to the drug.
2. Diabetic ketoacidosis, with or without coma. This condition should be treated with insulin.

WARNINGS

SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY

The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups (*Diabetes*, 19 (supp. 2): 747-830, 1970).

UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2% times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and advantages of DiaBeta® (glyburide) and of alternative modes of therapy.

Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure.

PRECAUTIONS:

General

Hypoglycemia: All sulfonylurea drugs are capable of producing severe hypoglycemia. Proper patient selection, dosage, and instructions are important to avoid hypoglycemic episodes. Renal or hepatic insufficiency may cause elevated blood levels of DiaBeta® (glyburide) and the latter may also diminish gluconeogenic capacity, both of which increase the risk of serious hypoglycemic reactions. Elderly, debilitated or malnourished patients, and those with adrenal or pituitary insufficiency are particularly susceptible to the hypoglycemic action of glucose-lowering drugs. Hypoglycemia may be difficult to recognize in the elderly and in people who are taking beta-adrenergic blocking drugs. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when alcohol is ingested, or when more than one glucose-lowering drug is used.

Loss of control of blood glucose: When a patient stabilized on any diabetic regimen is exposed to stress such as fever, trauma, infection, or surgery, a loss of control may occur. At such times, it may be necessary to discontinue DiaBeta® (glyburide) and administer insulin.

The effectiveness of any oral hypoglycemic drug, including DiaBeta® (glyburide), in lowering blood glucose to a desired level decreases in many patients over a period of time, which may be due to progression of the severity of the diabetes or to diminished responsiveness to the drug. This phenomenon is known as secondary failure, to distinguish it from primary failure in which the drug is ineffective in an individual patient when first given.

Information for patients

Patients should be informed of the potential risks, advantages, alternative modes of therapy, importance of adherence to dietary instructions, to a regular exercise program, and regular testing of urine and/or blood glucose. Also explain to the patient and responsible family members, the risks of hypoglycemia, its symptoms, treatment, conditions that predispose to its development, and primary and secondary failure.

Laboratory Tests

Blood and urine glucose should be monitored periodically. Measurement of glycosylated hemoglobin may be useful.

Drug Interactions

The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. When such drugs are administered to a patient receiving DiaBeta® (glyburide), the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving DiaBeta® (glyburide), the patient should be observed closely for loss of control.

Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving DiaBeta® (glyburide), the patient should be closely observed for loss of control. When such drugs are withdrawn from a patient receiving DiaBeta® (glyburide), the patient should be observed closely for hypoglycemia.

Carcinogenesis, Mutagenesis, and Impairment of Fertility

DiaBeta® (glyburide) is non-mutagenic when studied in the Salmonella microsome test (Ames test) and in the DNA damage/alkaline elution assay. Studies in rats at doses up to 300 mg/kg/day for 18 months showed no carcinogenic effects.

Pregnancy

Teratogenic Effects: Pregnancy Category B

Reproduction studies have been performed in rats and rabbits at doses up to 500 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to DiaBeta® (glyburide). There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Because recent information suggests that abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital abnormalities, many experts recommend that insulin be used during pregnancy to maintain blood glucose levels as close to normal as possible.

Nonteratogenic Effects:

Prolonged severe hypoglycemia (4 to 10 days) has been reported in neonates born to mothers who were receiving a sulfonylurea drug at the time of delivery. This has been reported more frequently with the use of agents with prolonged half-lives. If DiaBeta® (glyburide) is used during pregnancy, it should be discontinued at least two weeks before the expected delivery date.

Nursing Mothers

Although it is not known whether DiaBeta® (glyburide) is excreted in human milk, some sulfonylureas are known to be excreted in human milk. Because the potential for hypoglycemia in nursing infants may exist, a decision should be made whether to discontinue nursing or to discontinue administering the drug, taking into account the importance of the drug to the mother. If DiaBeta® (glyburide) is discontinued and if diet alone is inadequate for controlling blood glucose, insulin therapy should be considered.

PEDIATRIC USE

Safety and effectiveness in children have not been established.

ADVERSE REACTIONS

Hypoglycemia: See PRECAUTIONS and OVERDOSAGE Sections.

Gastrointestinal Reactions: Cholestatic jaundice may occur rarely; DiaBeta® (glyburide) should be discontinued if this occurs. Gastrointestinal disturbances, e.g., nausea, epigastric fullness, and heartburn, are the most common reactions and occur in 1.8% of treated patients. They tend to be dose-related and may disappear when dosage is reduced.

Dermatologic Reactions: Allergic skin reactions, e.g., pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions, occur in 1.5% of treated patients. These may be transient and may disappear despite continued use of DiaBeta® (glyburide); if skin reactions persist, the drug should be discontinued.

Porphyria cutanea tarda and photosensitivity reactions have been reported with sulfonylureas. **Hematologic Reactions:** Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, aplastic anemia, and pancytopenia have been reported with sulfonylureas.

Metabolic Reactions: Hepatic porphyria reactions have been reported with sulfonylureas; however, these have not been reported with DiaBeta® (glyburide). Disulfiram-like reactions have been reported very rarely with DiaBeta® (glyburide).

OVERDOSAGE: Overdosage can produce hypoglycemia. Aggressively treat the mild symptoms (without loss of consciousness or neurologic findings) with oral glucose and adjustments in drug dosage and/or meal patterns. Continue close monitoring until patient is out of danger. Severe hypoglycemic reactions with coma, seizure, or other neurological impairment, are medical emergencies requiring immediate hospitalization. With hypoglycemic coma (diagnosed or suspected), administer rapid intravenous injection of concentrated (50%) glucose solution, followed by continuous infusion of a more dilute (10%) glucose solution at a rate to maintain a blood glucose level above 100 mg/dl. Monitor closely for a minimum of 24-48 hours; hypoglycemia may recur after apparent clinical recovery.

YOUR PRESCRIPTIONS FOR
DIABETA®
(GLYBURIDE)
SUPPORT

DIABETES
RESEARCH & EDUCATION
FOUNDATION

Hoechst-Roussel Pharmaceuticals Inc.
Somerville, New Jersey 08876

Hoechst

Diabetologia

Clinical and Experimental Diabetes and Metabolism

Organ of the European Association for the Study of Diabetes (EASD)

Volume 28 Number 12 December 1985

Originals

B. Marner, T. Agner, C. Binder, Å. Lernmark, J. Nerup, T. Mandrup-Poulsen, S. Walldorff

Increased reduction in fasting C-peptide is associated with islet cell antibodies in Type 1 (insulin-dependent) diabetic patients 875

M. Krotkiewski, P. Lönnroth, K. Mandroukas, Z. Wroblewski, M. Rebuffé-Scrive, G. Holm, U. Smith, P. Björntorp

The effects of physical training on insulin secretion and effectiveness and on glucose metabolism in obesity and Type 2 (non-insulin-dependent) diabetes mellitus 881

M. J. Sheehy, J. R. Rowe, T. C. Fuller, E. J. Yunis, K. H. Gabbay

A minor subset of HLA-DR3 haplotypes is preferentially increased in Type 1 (insulin-dependent) diabetes 891

R. G. Tilton, A. M. Faller, J. K. Burkhardt, P. L. Hoffmann, C. Kilo, J. R. Williamson

Pericyte degeneration and acellular capillaries are increased in the feet of human diabetic patients 895

P. Lönnroth, C. Wesslau, G. Stenström, L.-E. Tisell, U. Smith

Reduced insulin binding to human fat cells following beta-adrenergic stimulation - experimental evidence and studies in patients with a pheochromocytoma 901

M. Viswanathan, V. Mohan, C. Snehalatha, A. Ramachandran

High prevalence of Type 2 (non-insulin-dependent) diabetes among the offspring of conjugal Type 2 diabetic parents in India 907

T. Awata, Y. Shibasaki, H. Hirai, T. Okabe, Y. Kanazawa, F. Takaku

Restriction fragment length polymorphism of the insulin gene region in Japanese diabetic and non-diabetic subjects 911

Y. Stefan, C. Bordin, S. Grasso, L. Orci

Beckwith-Wiedemann syndrome: a quantitative, immunohistochemical study of pancreatic islet cell populations 914

M. Ghiglione, E. Blazquez, L. O. Uttenthal, J. G. de Diego, E. Alvarez, S. K. George, S. R. Bloom

Glucagon-like peptide-1 does not have a role in hepatic carbohydrate metabolism 920

T. Ledet, L. Heickendorff

Growth hormone effect on accumulation of arterial basement membrane-like material studied on rabbit aortic myomedial cell cultures 922

D. G. Brocks, H. P. Neubauer, H. Strecker

Type IV collagen antigens in serum of diabetic rats: a marker for basement membrane collagen biosynthesis 928

Rapid communication

C. F. Gottfredson, K. Buschard, E. K. Frandsen

Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals 933

Workshop report

V. Jörgens, M. Berger

Second Eastern European Workshop on Diabetes Education of the Diabetes Education Study Group 936

Letters to the Editor

J. A. O'Hare, J. B. Ferriss

Transcapillary escape rate of albumin and extracellular fluid volume in diabetes 937

P. Fauchald, J. Norseth, J. Jervell

Reply from the authors 938

Organisation Section/Announcements 939

Author index 943

Subject index 946

Indexed in Current Contents



Springer International

125 Diabetologia - ISSN 0012-186X DBTGAJ 28 (12) 875-950 (1985)

FACULTY POSITION

Eye Research Institute of Retina Foundation

The Eye Research Institute is seeking an investigator whose research interests focus upon or can be applied to, the pathophysiology of diabetic retinopathy. Allied research areas could include cell biology, physiology, and biochemistry. Individuals should be willing to collaborate with both basic scientists and clinicians. Established investigators with ongoing funding are encouraged to apply; endowed funds are presently available for salary and/or research costs. Curriculum vitae and letter of interest should be forwarded to Sheldon M. Buzney, M.D., Search Committee, Eye Research Institute, 20 Staniford St., Boston, MA 02114. ERI is an affirmative action, equal opportunity employer.

CLINICAL NURSE SPECIALIST — DIABETES

Creative individual needed to develop and coordinate activities of an interdisciplinary team working with diabetic patients and their families. Major facets include inpatient and outpatient services, development/coordination of outreach programs, development of training programs/materials, development and presentation of staff inservice programs.

Requirements: RN, Master's in Nursing with specialization in Diabetes. Two years Clinical Nurse Specialist experience in health care organization, or equivalent, required. Two years experience in leadership role preferred.

St. Francis Regional Medical Center located in Wichita, Kansas is a progressive, non-profit, 886-bed acute care JCAH accredited teaching facility offering a vibrant atmosphere ideal for growth. The Wichita Community has a population of approximately 350,000 and offers numerous cultural and recreational activities.

Qualified candidates please submit resume in confidence or call collect to:

Marie O'Donnell
Human Resources Coordinator
Department of Human Resources
St. Francis Regional Medical Center
P.O. Box 1358 • Wichita, KS 67201
(316) 268-5764

EQUAL OPPORTUNITY EMPLOYER



ST. FRANCIS
REGIONAL
MEDICAL CENTER
WICHITA, KANSAS

BRIEF SUMMARY DIABINESE® (chlorpropamide) TABLETS, USP

CONTRAINDICATIONS

DIABINESE is contraindicated in patients with:
1. Known hypersensitivity to the drug.
2. Diabetic ketoacidosis, with or without coma. This condition should be treated with insulin.

WARNINGS

SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY
The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups (*Diabetes*, 19 [supp. 2]:747-830, 1970).

UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2 1/2 times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and advantages of DIABINESE and of alternative modes of therapy.

Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure.

PRECAUTIONS

General

Hypoglycemia: All sulfonylurea drugs are capable of producing severe hypoglycemia. Proper patient selection, dosage, and instructions are important to avoid hypoglycemic episodes. Renal or hepatic insufficiency may cause elevated blood levels of DIABINESE and the latter may also diminish gluconeogenic capacity, both of which increase the risk of serious hypoglycemic reactions. Elderly, debilitated or malnourished patients, and those with adrenal or pituitary insufficiency are particularly susceptible to the hypoglycemic action of glucose-lowering drugs. Hypoglycemia may be difficult to recognize in the elderly, and in people who are taking beta-adrenergic blocking drugs. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when alcohol is ingested, or when more than one glucose-lowering drug is used.

Because of the long half-life of chlorpropamide, patients who become hypoglycemic during therapy require careful supervision of the dose and frequent feedings for at least 3 to 5 days. Hospitalization and intravenous glucose may be necessary.

Loss of control of blood glucose: When a patient stabilized on any diabetic regimen is exposed to stress such as fever, trauma, infection, or surgery, a loss of control may occur. At such times, it may be necessary to discontinue DIABINESE and administer insulin.

The effectiveness of any oral hypoglycemic drug, including DIABINESE, in lowering blood glucose to a desired level decreases in many patients over a period of time, which may be due to progression of the severity of the diabetes or to diminished responsiveness to the drug. This phenomenon is known as secondary failure, to distinguish it from primary failure in which the drug is ineffective in an individual patient when first given.

ADVERSE REACTIONS

Hypoglycemia: See PRECAUTIONS section.

Gastrointestinal Reactions: Cholestatic jaundice may occur rarely; DIABINESE should be discontinued if this occurs. Gastrointestinal disturbances are the most common reactions, nausea has been reported in less than 5% of patients, and diarrhea, vomiting, anorexia, and hunger in less than 2%. Other gastrointestinal disturbances have occurred in less than 1% of patients including proctocolitis. They tend to be dose related and may disappear when dosage is reduced.

Dermatologic Reactions: Pruritus has been reported in less than 3% of patients. Other allergic skin reactions, e.g., urticaria and maculopapular eruptions have been reported in approximately 1% or less of patients. These may be transient and may disappear despite continued use of DIABINESE; if skin reactions persist the drug should be discontinued.

Porphyrinuria cutanea tarda and photosensitivity reactions have been reported with sulfonylureas. Skin eruptions rarely progressing to erythema multiforme and exfoliative dermatitis have also been reported.

Hematologic Reactions: Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, aplastic anemia, pancytopenia and eosinophilia have been reported with sulfonylureas.

Metabolic Reactions: Hepatic porphyria and disulfiram-like reactions have been reported with DIABINESE.

Endocrine Reactions: On rare occasions, chlorpropamide has caused a reaction identical to the syndrome of inappropriate antidiuretic hormone (ADH) secretion. The features of this syndrome result from excessive water retention and include hyponatremia, low serum osmolality, and high urine osmolality.

DOSAGE AND ADMINISTRATION

There is no fixed dosage regimen for the management of diabetes mellitus with DIABINESE or any other hypoglycemic agent. In addition to the usual monitoring of urinary glucose, the patient's blood glucose must also be monitored periodically to determine the minimum effective dose for the patient, to detect primary failure, and to detect secondary failure. Glycosylated hemoglobin levels may also be of value in monitoring the patient's response to therapy.

The total daily dosage is generally taken at a single time each morning with breakfast. Occasionally cases of gastrointestinal intolerance may be relieved by dividing the daily dosage. A LOADING OR PRIMING DOSE IS NOT NECESSARY AND SHOULD NOT BE USED.

Initial Therapy: 1. The mild to moderately severe, middle-aged, stable, non-insulin-dependent diabetic patient should be started on 250 mg daily. Older patients should be started on smaller amounts of DIABINESE, in the range of 100 to 125 mg daily.

2. No transition period is necessary when transferring patients from other oral hypoglycemic agents to DIABINESE. The other agent may be discontinued abruptly and chlorpropamide started at once. In prescribing chlorpropamide, due consideration must be given to its greater potency. Many mild to moderately severe, middle-aged, stable non-insulin-dependent diabetic patients receiving insulin can be placed directly on the oral drug and their insulin abruptly discontinued. For patients requiring more than 40 units of insulin daily, therapy with DIABINESE may be initiated with a 50 per cent reduction in insulin for the first few days, with subsequent further reductions dependent upon the response.

Five to seven days after the initial therapy, the blood level of chlorpropamide reaches a plateau. Dosage may subsequently be adjusted upward or downward by increments of not more than 50 to 125 mg at intervals of three to five days to obtain optimal control. More frequent adjustments are usually undesirable.

Maintenance Therapy: Most moderately severe, middle-aged, stable non-insulin-dependent diabetic patients are controlled by approximately 250 mg daily. Many investigators have found that some milder diabetics do well on daily doses of 100 mg or less. Many of the more severe diabetics may require 500 mg daily for adequate control. PATIENTS WHO DO NOT RESPOND COMPLETELY TO 500 MG DAILY WILL USUALLY NOT RESPOND TO HIGHER DOSES. MAINTENANCE DOSES ABOVE 750 MG DAILY SHOULD BE AVOIDED.

HOW SUPPLIED

Blue, D-shaped, scored tablets in strengths of 100 mg, tablet code 393, (100's, NDC# 0663-3930-66; 500's, NDC# 0663-3930-73; and 100 unit dose of 10 x 10, NDC# 0663-3930-41) and 250 mg, tablet code 394, (100's, NDC# 0663-3940-66, 250's, NDC# 0663-3940-71, 1000's, NDC# 0663-3940-82; 100 unit dose of 10 x 10, NDC# 0663-3940-41, and 30's D-Pak, NDC# 0663-3940-30).

RECOMMENDED STORAGE: Store below 86°F (30°C).

CAUTION: Federal law prohibits dispensing without prescription.



LABORATORIES DIVISION
PFIZER INC



For the money saved with generic chlorpropamide, your patient couldn't even call your office.

Diabinese® (chlorpropamide) costs about 20¢ to 25¢* a day more than generic chlorpropamide—less than most local pay phone calls.


For your patients who have been doing well on Diabinese, why change?

To be sure there's no change from Diabinese, specify: Dispense As Written, Do Not Substitute, or Medically Necessary, depending on the state in which you practice.


DIABINESE® Tablets, USP
(chlorpropamide) 100 mg, 250 mg
and D-Pak

*Source: PDS Alpha, New Product Tracking Report, Pharmaceutical Data Services, February 1985.

Pfizer LABORATORIES DIVISION
PFIZER INC.



BEHIND THE FACE
OF HYPERTENSION
New evidence for central control



For the obese hypertensive

“Hyperactivity of the sympathetic nervous system may be a major factor in the pathogenesis of hypertension in obesity.”¹

*Effective central control
of blood pressure*


Tablets of 0.1, 0.2, 0.3 mg
Catapres[®]
(clonidine HCl)

Hypertension

Please see last page for brief summary, including warnings, precautions, and adverse reactions.

BEHIND THE FACE OF HYPERTENSION

New evidence for central control



Catapres® (clonidine HCl)

Hypertension

Catapres®

(clonidine hydrochloride)
Tablets of 0.1, 0.2, 0.3 mg

Indication: The drug is indicated in the treatment of hypertension. As an anti-hypertensive drug, Catapres (clonidine hydrochloride) is mild to moderate in potency. It may be employed in a general treatment program with a diuretic and/or other antihypertensive agents as needed for proper patient response.

Warnings: Tolerance may develop in some patients necessitating a reevaluation of therapy.

Usage in Pregnancy: In view of embryotoxic findings in animals, and since information on possible adverse effects in pregnant women is limited to uncontrolled clinical data, the drug is not recommended in women who are or may become pregnant unless the potential benefits outweigh the potential risk to mother and fetus.

Usage in Children: No clinical experience is available with the use of Catapres (clonidine hydrochloride) in children.

Precautions: When discontinuing Catapres (clonidine hydrochloride), reduce the dose gradually over 2 to 4 days to avoid a possible rapid rise in blood pressure and associated subjective symptoms such as nervousness, agitation, and headache. Patients should be instructed not to discontinue therapy without consulting their physician. Rare instances of hypertensive encephalopathy and death have been recorded after cessation of clonidine hydrochloride therapy. A causal relationship has not been established in these cases. It has been demonstrated that an excessive rise in blood pressure, should it occur, can be reversed by resumption of clonidine hydrochloride therapy or by intravenous phentolamine. Patients who engage in potentially hazardous activities, such as operating machinery or driving, should be advised of the sedative effect. This drug may enhance the CNS-depressive effects of alcohol, barbiturates and other sedatives. Like any other agent lowering blood pressure, clonidine hydrochloride should be used with caution in patients with severe coronary insufficiency, recent myocardial infarction, cerebrovascular disease or chronic renal failure.

As an integral part of their overall long-term care, patients treated with Catapres (clonidine hydrochloride) should receive periodic eye examinations. While, except for some dryness of the eyes, no drug-related abnormal ophthalmologic findings have been recorded with Catapres (clonidine hydrochloride), in several studies the drug produced a dose-dependent increase in the incidence and severity of spontaneously occurring retinal degeneration in albino rats treated for 6 months or longer.

Adverse Reactions: The most common reactions are dry mouth, drowsiness and sedation. Constipation, dizziness, headache, and fatigue have been reported. Generally these effects tend to diminish with continued therapy. The following reactions have been associated with the drug, some of them rarely. (In some instances an exact causal relationship has not been established.) These include: Anorexia, malaise, nausea, vomiting, parotid pain, mild transient abnormalities in liver function tests; one report of possible drug-induced hepatitis without icterus and hyperbilirubinemia in a patient receiving clonidine hydrochloride, chlorthalidone and papaverine hydrochloride. Weight gain, transient elevation of blood glucose, or serum creatine phosphokinase; congestive heart failure, Raynaud's phenomenon; vivid dreams or nightmares, insomnia, other behavioral changes, nervousness, restlessness, anxiety and mental depression. Also rash, angioneurotic edema, hives, urticaria, thinning of the hair, pruritus not associated with a rash, impotence, urinary retention, increased sensitivity to alcohol, dryness, itching or burning of the eyes, dryness of the nasal mucosa, pallor, gynecomastia, weakly positive Coombs test, asymptomatic electrocardiographic abnormalities manifested as Wenckebach period or ventricular trigeminy.

Overdosage: Profound hypotension, weakness, somnolence, diminished or absent reflexes and vomiting followed the accidental ingestion of Catapres (clonidine hydrochloride) by several children from 19 months to 5 years of age. Gastric lavage and administration of an analeptic and vasopressor led to complete recovery within 24 hours. Tolazoline in intravenous doses of 10 mg at 30-minute intervals usually abolishes all effects of Catapres (clonidine hydrochloride) overdosage.

How Supplied: Catapres, brand of clonidine hydrochloride, is available as 0.1 mg (tan) and 0.2 mg (orange) oval, single-scored tablets in bottles of 100 and 1000 and unit dose package of 100. Also available as 0.3 mg (peach) oval, single-scored tablets in bottles of 100.

For complete details, please see full prescribing information.
Under license from Boehringer Ingelheim International GmbH

Reference:

1. Pioneering Research in Hypertension: The Role of the Sympathetic Nervous System, film and monograph, Boehringer Ingelheim Ltd., 1982.



**Boehringer
Ingelheim**

Boehringer Ingelheim Ltd
Ridgefield, CT 06877

AMERICAN DIABETES ASSOCIATION HAS MOVED TO ALEXANDRIA, VIRGINIA

In order to serve ADA's constituency more effectively and to carry out the mission of the Association, ADA has moved its National Service Center from New York City to Alexandria, Virginia.


Mail to ADA should be addressed to:
American Diabetes Association, Inc.
National Service Center
1660 Duke Street
Alexandria, VA 22314
Phone: (800) ADA-DISC
(703) 549-1500



Glucotrol[®]
(glipizide) 5-mg and 10-mg
Scored Tablets

Breaking barriers

more normal insulin release and utilization



(Adapted from Peterson CM, et al¹)

Glucose and insulin response to three standard meals was measured at eleven time points on the first and fifteenth days of administration of Glucotrol (glipizide) to seven patients with NIDDM. The mean dose of Glucotrol was 8.7 mg per day (0.1 mg/kg).

■ Insulin levels rose markedly after the first meal, then dropped, then rose again following subsequent meals.

■ The insulin response pattern with Glucotrol closely simulates the pattern commonly seen in nondiabetics.

References: 1. Peterson CM, Sims RV, Jones RL, et al: Bioavailability of glipizide and its effect on blood glucose and insulin levels in patients with non-insulin-dependent diabetes. *Diabetes Care* 1982; 5:497-500. 2. Melander A, Wåhlin-Boll E: Clinical pharmacology of glipizide, in *Proceedings of a Symposium: New Perspectives in Noninsulin-Dependent Diabetes Mellitus and the Role of Glipizide in Its Treatment*. *Am J Med*, pp. 41-45, Nov. 30, 1983. 3. Feinglos MN, Lebovitz HE: Long-term safety and efficacy of glipizide, in *Proceedings of a Symposium: New Perspectives in Noninsulin-Dependent Diabetes Mellitus and the Role of Glipizide in Its Treatment*. *Am J Med*, pp. 60-66, Nov. 30, 1983.

ROERIG 

to glucose control in NIDDM

with significant advantages
for many NIDDM patients

Rapid, consistent therapeutic action "The aim of sulfonylurea treatment should be complete normalization of glucose economy... therefore, the sulfonylurea should be potent and rapid-acting. Moreover, it should have complete bioavailability in order to minimize variations between and within individual subjects.
"Glipizide [Glucotrol] has complete bioavailability and its absorption and onset of action are very rapid."²

Rapid excretion, inactive metabolites "As glipizide [Glucotrol] is very rapidly eliminated, and as there is no evidence that its metabolites are significantly active, the risk of long-lasting hypoglycemia should be small...."² However, as with all sulfonylureas, hypoglycemia may occur.

Long-term metabolic improvement "Long-term therapy with glipizide, in contrast to studies of other sulfonylureas, often results in a sustained increase in glucose-stimulated insulin secretion."³

While controversy remains in the findings of the UGDP, there have been reports of increased cardiovascular risk associated with oral hypoglycemic therapy.

Glucotrol[®]

(glipizide) 5-mg and 10-mg
Scored Tablets

When diet alone fails in non-insulin-dependent diabetes mellitus

Please turn page for Glucotrol[®] (glipizide) prescribing information.

GLUCOTROL® (glipizide) Tablets
Brief Summary of Prescribing Information

INDICATIONS AND USAGE: GLUCOTROL is indicated as an adjunct to diet for the control of hyperglycemia in patients with non-insulin-dependent diabetes mellitus (NIDDM, type II) after an adequate trial of dietary therapy has proved unsatisfactory.

CONTRAINDICATIONS: GLUCOTROL is contraindicated in patients with known hypersensitivity to the drug or with diabetic ketoacidosis, with or without coma, which should be treated with insulin.

SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY: The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups (*Diabetes* 19, suppl 2:747-830, 1970).

UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2-1/2 times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and advantages of GLUCOTROL and of alternative modes of therapy.

Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure.

PRECAUTIONS: Renal and Hepatic Disease: The metabolism and excretion of GLUCOTROL may be slowed in patients with impaired renal and/or hepatic function. Hypoglycemia may be prolonged in such patients should it occur.

Hypoglycemia: All sulfonylureas are capable of producing severe hypoglycemia. Proper patient selection, dosage and instructions are important to avoid hypoglycemia. Renal or hepatic insufficiency may increase the risk of hypoglycemic reactions. Elderly, debilitated, or malnourished patients and those with adrenal or pituitary insufficiency are particularly susceptible to the hypoglycemic action of glucose-lowering drugs. Hypoglycemia may be difficult to recognize in the elderly or people taking beta-adrenergic blocking drugs. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when alcohol is ingested, or when more than one glucose-lowering drug is used.

Loss of Control of Blood Glucose: A loss of control may occur in diabetic patients exposed to stress such as fever, trauma, infection or surgery. It may then be necessary to discontinue GLUCOTROL and administer insulin.

Laboratory Tests: Blood and urine glucose should be monitored periodically. Measurement of glycosylated hemoglobin may be useful.

Information for Patients: Patients should be informed of the potential risks and advantages of GLUCOTROL, of alternative modes of therapy, as well as the importance of adhering to dietary instructions, of a regular exercise program, and of regular testing of urine and/or blood glucose. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members. Primary and secondary failure should also be explained.

Drug Interactions: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including non-steroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents. *In vitro* studies indicate that GLUCOTROL binds differently than tolbutamide and does not interact with salicylate or dicumarol. However, caution must be exercised in extrapolating these findings to a clinical situation. Certain drugs tend to produce hyperglycemia and may lead to loss of control, including the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.

Carcinogenesis, Mutagenesis, Impairment of Fertility: A 20-month study in rats and an 18-month study in mice at doses up to 75 times the maximum human dose revealed no evidence of drug-related carcinogenicity. Bacterial and *in vivo* mutagenicity tests were uniformly negative. Studies in rats of both sexes at doses up to 75 times the human dose showed no effects on fertility.

Pregnancy: Pregnancy Category C. GLUCOTROL (glipizide) was found to be mildly fetotoxic in rat reproductive studies at all dose levels (5-50 mg/kg). This fetotoxicity has been similarly noted with other sulfonylureas, such as tolbutamide and tolazamide. The effect is perinatal and believed to be directly related to the pharmacologic (hypoglycemic) action of GLUCOTROL. In studies in rats and rabbits no teratogenic effects were found. There are no adequate and well-controlled studies in pregnant women. GLUCOTROL should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Because recent information suggests that abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital abnormalities, many experts recommend that insulin be used during pregnancy to maintain blood glucose levels as close to normal as possible.

Nonteratogenic Effects: Prolonged severe hypoglycemia has been reported in neonates born to mothers who were receiving a sulfonylurea drug at the time of delivery. This has been reported more frequently with the use of agents with prolonged half-lives. GLUCOTROL should be discontinued at least one month before the expected delivery date.

Nursing Mothers: Since some sulfonylurea drugs are known to be excreted in human milk, insulin therapy should be considered if nursing is to be continued.

Pediatric Use: Safety and effectiveness in children have not been established.

ADVERSE REACTIONS: In controlled studies, the frequency of serious adverse reactions reported was very low. Of 702 patients, 11.8% reported adverse reactions and in only 1.5% was GLUCOTROL discontinued.

Hypoglycemia: See PRECAUTIONS and OVERDOSAGE sections.

Gastrointestinal: Gastrointestinal disturbances, the most common, were reported with the following approximate incidence: nausea and diarrhea, one in 70; constipation and gastralgia, one in 100. They appear to be dose-related and may disappear on division or reduction of dosage. Cholestatic jaundice may occur rarely with sulfonylureas: GLUCOTROL should be discontinued if this occurs.

Dermatologic: Allergic skin reactions including erythema, morbilliform or maculopapular eruptions, urticaria, pruritus, and eczema have been reported in about one in 70 patients. These may be transient and may disappear despite continued use of GLUCOTROL; if skin reactions persist, the drug should be discontinued. Porphyria cutanea tarda and photosensitivity reactions have been reported with sulfonylureas.

Hematologic: Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, aplastic anemia, and pancytopenia have been reported with sulfonylureas.

Metabolic: Hepatic porphyria and disulfiram-like alcohol reactions have been reported with sulfonylureas. Clinical experience to date has shown that GLUCOTROL has an extremely low incidence of disulfiram-like reactions.

Miscellaneous: Dizziness, drowsiness, and headache have each been reported in about one in fifty patients treated with GLUCOTROL. They are usually transient and seldom require discontinuance of therapy.

OVERDOSAGE: Overdosage of sulfonylureas including GLUCOTROL can produce hypoglycemia. If hypoglycemic coma is diagnosed or suspected, the patient should be given a rapid intravenous injection of concentrated (50%) glucose solution. This should be followed by a continuous infusion of a more dilute (10%) glucose solution at a rate that will maintain the blood glucose at a level above 100 mg/dL. Patients should be closely monitored for a minimum of 24 to 48 hours since hypoglycemia may recur after apparent clinical recovery. Clearance of GLUCOTROL from plasma would be prolonged in persons with liver disease. Because of the extensive protein binding of GLUCOTROL (glipizide), dialysis is unlikely to be of benefit.

DOSE AND ADMINISTRATION: There is no fixed dosage regimen for the management of diabetes mellitus with GLUCOTROL; in general, it should be given approximately 30 minutes before a meal to achieve the greatest reduction in postprandial hyperglycemia.

Initial Dose: The recommended starting dose is 5 mg before breakfast. Geriatric patients or those with liver disease may be started on 2.5 mg. Dosage adjustments should ordinarily be in increments of 2.5-5 mg, as determined by blood glucose response. At least several days should elapse between titration steps.

Maximum Dose: The maximum recommended total daily dose is 40 mg.

Maintenance: Some patients may be effectively controlled on a once-a-day regimen, while others show better response with divided dosing. Total daily doses above 15 mg should ordinarily be divided.


HOW SUPPLIED: GLUCOTROL is available as white, dye-free, scored diamond-shaped tablets imprinted as follows: 5 mg tablet—Pfizer 411 (NDC 5 mg 0049-4110-66) Bottles of 100; 10 mg tablet—Pfizer 412 (NDC 10 mg 0049-4120-66) Bottles of 100.

CAUTION: Federal law prohibits dispensing without prescription.

More detailed professional information available on request.

ROERIG  A division of Pfizer Pharmaceuticals
 New York, New York 10017

Preserve your copies of diabetes



Custom-made for DIABETES, these journal slipcases and binders turn back issues into a permanent reference source. Bound in attractive blue leatherette, and embossed with gold lettering, 1 slipcase or 2 binders holds 1 year of DIABETES (12 issues plus supplements). And each comes with gold transfers, allowing you to personalize your volume further. These durable, space saving cases make affordable gifts as well.

SLIPCASSES: \$6.95 each, three for \$20.00, six for \$36.00 (measures: 11½ x 8½ x 4¾")

BINDERS: \$8.50 each, three for \$24.75, six for \$48.00 (measures: 12¾ x 9¼ x 3½")

MAIL TO: Jesse Jones Industries (Since 1843), P.O. Box 5120, Dept. DIAB, Philadelphia, PA 19141

Enclosed is my check or money order for \$_____. Please send me: _____ slipcases
 _____ binders. (U.S. funds only)


NAME _____ (please print)

ADDRESS _____

CITY _____ STATE _____ ZIP _____

NOTE: Satisfaction guaranteed or money refunded. Allow 5 to 6 weeks delivery. Add \$2.50 each outside U.S. Slipcases and binders also available for DIABETES & DIABETES FORECAST. For information write: American Diabetes Association, National Service Center, 1660 Duke St. P.O. Box 25757, Alexandria, VA 22313, Attn: Circulation Dept.






*EIGHT YEARS AND
4,000,000 PATIENTS LATER...*

*THE
PROMISE OF
ACE* INHIBITION
IS RECOGNIZED...*

*Angiotensin Converting Enzyme

†Worldwide.


SQUIBB



“With [CAPOTEN[®] (captopril tablets)]
it appears that for the first time ever a
patient can feel as well on treatment for
high blood pressure as he does off it.”¹

*Angiotensin Converting Enzyme

†CAPOTEN may be used as initial therapy only for patients with normal renal function in whom the risk of neutropenia/agranulocytosis is relatively low (1 out of over 8,600 in clinical trials). Use special precautions in patients with impaired renal function, collagen vascular disorders, or those exposed to other drugs known to affect the white cells or immune response. Evaluation of hypertensives should always include assessment of renal function. See INDICATIONS AND USAGE, WARNINGS, and ADVERSE REACTIONS in the brief summary on the adjacent page.

‡The most frequently occurring adverse reactions are skin rash and taste alteration; both effects are generally mild, reversible, or self-limited.

Expanded Prescribing Freedom—
Mild-to-Moderate Hypertension

Capoten for Initial Therapy of Hypertension[†]



Fatigue, loss of libido, impotence, and mental impairment almost never occur[‡]

Effective alone or in combination with diuretics

Convenient bid dosage

ACE*INHIBITOR
CAPOTEN[®]
(captopril tablets)

FIRST-LINE THERAPY THAT PUTS
QUALITY OF LIFE FIRST

CAPOTEN® TABLETS
Captopril Tablets

INDICATIONS: Hypertension—CAPOTEN (captopril) is indicated for the treatment of hypertension. Consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS). CAPOTEN may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for those who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. CAPOTEN is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics.

Heart Failure: CAPOTEN (captopril) is indicated in patients with heart failure who have not responded adequately to or cannot be controlled by conventional diuretic and digitalis therapy. CAPOTEN is to be used with diuretics and digitalis.

WARNINGS: Neutropenia/Agranulocytosis—Neutropenia ($<1000/\text{mm}^3$) with myeloid hypoplasia has resulted from use of captopril. About half of the neutropenic patients developed systemic or oral cavity infections or other features of the syndrome of agranulocytosis. The risk of neutropenia is dependent on the clinical status of the patient:

In clinical trials in patients with hypertension who have normal renal function (serum creatinine <1.6 mg/dL and no collagen vascular disease), neutropenia has been seen in one patient out of over 8,600 exposed. In patients with some degree of renal failure (serum creatinine at least 1.6 mg/dL) but no collagen vascular disease, the risk in clinical trials was about 1 per 500. Doses were relatively high in these patients, particularly in view of their diminished renal function. In patients with collagen vascular diseases (e.g., systemic lupus erythematosus, scleroderma) and impaired renal function, neutropenia occurred in 3.7% of patients in clinical trials. While none of the over 750 patients in formal clinical trials of heart failure developed neutropenia, it has occurred during subsequent clinical experience. Of reported cases, about half had serum creatinine ≥ 1.6 mg/dL and more than 75% received procainamide. In heart failure, it appears that the same risk factors for neutropenia are present.

Neutropenia has appeared usually within 3 months after starting therapy, associated with myeloid hypoplasia and frequently accompanied by erythroid hypoplasia and decreased numbers of megakaryocytes (e.g., hypoplastic bone marrow and pancytopenia); anemia and thrombocytopenia were sometimes seen. Neutrophils generally returned to normal in about 2 weeks after captopril was discontinued, and serious infections were limited to clinically complex patients. About 13% of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors.

Evaluation of the hypertensive or heart failure patient should always include assessment of renal function. If captopril is used in patients with impaired renal function, white blood cell and differential counts should be evaluated prior to starting treatment and at approximately 2-week intervals for about 3 months, then periodically. In patients with collagen vascular disease or who are exposed to other drugs known to affect the white cells or immune response, particularly when there is impaired renal function, captopril should be used only after an assessment of benefit and risk, and then with caution. All patients treated with captopril should be told to report any signs of infection (e.g., sore throat, fever); if infection is suspected, perform counts without delay. Since discontinuation of captopril and other drugs has generally led to prompt return of the white count to normal, upon confirmation of neutropenia (neutrophil count $<1000/\text{mm}^3$) withdraw captopril and closely follow the patient's course.

Proteinuria—Total urinary proteins >1 g/day were seen in about 0.7% of patients on captopril. About 90% of affected patients had evidence of prior renal disease or received high doses (>150 mg/day), or both. The nephrotic syndrome occurred in about one-fifth of proteinuric patients. In most cases, proteinuria subsided or cleared within 6 months whether or not captopril was continued. The BUN and creatinine were seldom altered in proteinuric patients. Since most cases of proteinuria occurred by the 8th month of therapy, patients with prior renal disease or those receiving captopril at doses >150 mg/day should have urinary protein estimates (dip-stick on 1st morning urine) before therapy, and periodically thereafter.

Hypotension—Excessive hypotension was rarely seen in hypertensive patients but is a possibility in severely salt/volume-depleted persons such as those treated vigorously with diuretics (see PRECAUTIONS [Drug Interactions]).

In heart failure, where blood pressure was either normal or low, transient decreases in mean blood pressure $>20\%$ were recorded in about half of the patients. This transient hypotension may occur after any of the first several doses and is usually well tolerated, although rarely it has been associated with arrhythmia or conduction defects. A starting dose of 6.25 or 12.5 mg tid may minimize the hypotensive effect. Patients should be followed closely for the first 2 weeks of treatment and whenever the dose of captopril and/or diuretic is increased.

BECAUSE OF THE POTENTIAL FALL IN BLOOD PRESSURE IN THESE PATIENTS, THERAPY SHOULD BE STARTED UNDER VERY CLOSE MEDICAL SUPERVISION.

PRECAUTIONS: General: Impaired Renal Function, Hypertension—Some hypertensive patients with renal disease, particularly those with severe renal artery stenosis, have developed increases in BUN and serum creatinine. It may be necessary to reduce captopril dosage and/or discontinue diuretic. For some of these patients, normalization of blood pressure and maintenance of adequate renal perfusion may not be possible. **Heart Failure**—About 20% of patients develop stable elevations of BUN and serum creatinine $>20\%$ above normal or baseline upon long-term treatment. Less than 5% of patients, generally with severe preexisting renal disease, required discontinuation due to progressively increasing creatinine. See DOSAGE AND ADMINISTRATION, ADVERSE REACTIONS [Altered Laboratory Findings]. **Valvular Stenosis**—A theoretical concern, for risk of decreased coronary perfusion, has been noted regarding vasodilator treatment in patients with aortic stenosis due to decreased afterload reduction.

Surgery/Anesthesia—If hypotension occurs during major surgery or anesthesia, and is considered due to the effects of captopril, it is correctable by volume expansion.

Reference:

1. Stumpe KO, Overlack A, Kolloch R, et al: Long-term efficacy of angiotensin-converting-enzyme inhibition with captopril in mild-to-moderate essential hypertension. *Br J Clin Pharmacol* 14(suppl 2):121S-126S, 1982.

Drug Interactions: Hypotension: Patients on Diuretic Therapy—Precipitous reduction of blood pressure may occasionally occur within the 1st hour after administration of the initial captopril dose in patients on diuretics, especially those recently placed on diuretics, and those on severe dietary salt restriction or dialysis. This possibility can be minimized by either discontinuing the diuretic or increasing the salt intake about 1 week prior to initiation of captopril therapy or by initiating therapy with small doses (6.25 or 12.5 mg). Alternatively, provide medical supervision for at least 1 hour after the initial dose.

Agents Having Vasodilator Activity—In heart failure patients, vasodilators should be administered with caution.

Agents Causing Renin Release—Captopril's effect will be augmented by antihypertensive agents that cause renin release.

Agents Affecting Sympathetic Activity—The sympathetic nervous system may be especially important in supporting blood pressure in patients receiving captopril alone or with diuretics. Beta-adrenergic blocking drugs add some further antihypertensive effect to captopril, but the overall response is less than additive. Therefore, use agents affecting sympathetic activity (e.g., ganglionic blocking agents or adrenergic neuron blocking agents) with caution.

Agents Increasing Serum Potassium—Give potassium-sparing diuretics or potassium supplements only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium. Use potassium-containing salt substitutes with caution.

Inhibitors of Endogenous Prostaglandin Synthesis—Indomethacin and other nonsteroidal anti-inflammatory agents may reduce the antihypertensive effect of captopril, especially in low renin hypertension.

Drug/Laboratory Test Interaction: Captopril may cause a false-positive urine test for acetone.

Carcinogenesis, Mutagenesis and Impairment of Fertility: Two-year studies with doses of 50 to 1350 mg/kg/day in mice and rats failed to show any evidence of carcinogenic potential. Studies in rats have revealed no impairment of fertility.

Pregnancy: Category C—There are no adequate and well-controlled studies in pregnant women. Embryocidal effects and craniofacial malformations were observed in rabbits. Therefore, captopril should be used during pregnancy, or for patients likely to become pregnant, only if the potential benefit outweighs the potential risk to the fetus. Captopril crosses the human placenta.

Nursing Mothers: Captopril is secreted in human milk. Exercise caution when administering captopril to a nursing woman, and, in general, nursing should be interrupted.

Pediatric Use: Safety and effectiveness in children have not been established although there is limited experience with use of captopril in children from 2 months to 15 years of age. Dosage, on a weight basis, was comparable to that used in adults. Captopril should be used in children only if other measures for controlling blood pressure have not been effective.

ADVERSE REACTIONS: Reported incidences are based on clinical trials involving approximately 7000 patients.

Renal—About 1 of 100 patients developed proteinuria (see WARNINGS). Renal insufficiency, renal failure, polyuria, oliguria, and urinary frequency in 1 to 2 of 1000 patients.

Hematologic—Neutropenia/agranulocytosis have occurred (see WARNINGS). Anemia, thrombocytopenia, and pancytopenia have been reported.

Dermatologic—Rash (usually maculopapular, rarely urticarial), often with pruritus and sometimes with fever and eosinophilia, in about 4 to 7 of 100 patients (depending on renal status and dose), usually during the 1st 4 weeks of therapy. Pruritus, without rash, in about 2 of 100 patients. A reversible associated pemphigoid-like lesion, and photosensitivity have also been reported. Angioedema of the face, mucous membranes of the mouth, or of the extremities in about 1 of 1000 patients—reversible on discontinuance of captopril therapy. One case of laryngeal edema reported. Flushing or pallor in 2 to 5 of 1000 patients.

Cardiovascular—Hypotension may occur, see WARNINGS and PRECAUTIONS (Drug Interactions) for discussion of hypotension on initiation of captopril therapy. Tachycardia, chest pain, and palpitations each in about 1 of 100 patients. Angina pectoris, myocardial infarction, Raynaud's syndrome, and congestive heart failure each in 2 to 3 of 1000 patients.

Dysgeusia—About 2 to 4 (depending on renal status and dose) of 100 patients developed a diminution or loss of taste perception; taste impairment is reversible and usually self-limited even with continued drug use (2 to 3 months). Gastric irritation, abdominal pain, nausea, vomiting, diarrhea, anorexia, constipation, aphthous ulcers, peptic ulcer, dizziness, headache, malaise, fatigue, insomnia, dry mouth, dyspnea, cough, alopecia, and paresthesias reported in about 0.5 to 2% of patients but did not appear at increased frequency compared to placebo or other treatments used in controlled trials.

Altered Laboratory Findings: Elevations of liver enzymes in a few patients although no causal relationship has been established. Rarely cholestatic jaundice and hepatocellular injury with or without secondary cholestasis, have been reported. A transient elevation of BUN and serum creatinine may occur, especially in volume-depleted or renovascular hypertensive patients. In instances of rapid reduction of longstanding or severely elevated blood pressure, the glomerular filtration rate may decrease transiently, also resulting in transient rises in serum creatinine and BUN. Small increases in serum potassium concentration frequently occur, especially in patients with renal impairment (see PRECAUTIONS).

OVERDOSAGE: Primary concern is correction of hypotension. Volume expansion with an I.V. infusion of normal saline is the treatment of choice for restoration of blood pressure. Captopril may be removed from the general circulation by hemodialysis.

DOSAGE AND ADMINISTRATION: CAPOTEN (captopril) should be taken one hour before meals. In hypertension, CAPOTEN may be dosed bid or tid. Dosage must be individualized; see DOSAGE AND ADMINISTRATION section of package insert for detailed information regarding dosage in hypertension and in heart failure. Because CAPOTEN (captopril) is excreted primarily by the kidneys, dosage adjustments are recommended for patients with impaired renal function.

Consult package insert before prescribing CAPOTEN (captopril).

HOW SUPPLIED: Available in tablets of 12.5, 25, 50, and 100 mg in bottles of 100 (25 mg also available in bottles of 1000), and in UNIMATIC® single dose packs of 100 tablets. (J3-658D)



INNOVATORS IN CARDIOVASCULAR MEDICINE

© 1986 E. R. Squibb & Sons, Inc., Princeton, NJ 08540 526-553 Issued: January 1986



The Diabetes Research and Education Foundation, Inc. is soliciting grant requests for promising initiatives in the field of diabetes research and education. The Foundation is an independent, non-profit organization with a Board of Trustees comprised of specialists in diabetes research, clinical practice, pharmacy and patient education. The Board meets twice per year to review grant requests and disburse awards. Individual grant awards are currently limited to \$20,000.

To be considered at the next meeting, which is scheduled for late April, grant applications must be received by March 15, 1986. Applications can be obtained by writing to:

Diabetes Research and Education Foundation, Inc.
P.O. Box 6168
Bridgewater, N.J. 08807-9998
ATTENTION: Herbert Rosenkilde, M.D., Executive Director

DO3003-186

**NATIONAL INSTITUTES OF HEALTH
NATIONAL INSTITUTE OF ARTHRITIS, DIABETES, & DIGESTIVE
& KIDNEY DISEASES
PHOENIX EPIDEMIOLOGY & CLINICAL RESEARCH BRANCH
CLINICAL DIABETES & NUTRITION SECTION
PHOENIX, ARIZONA
MEDICAL STAFF FELLOW**

This position is located in the Clinical Diabetes & Nutrition Section of the Phoenix Epidemiology & Clinical Research Branch, National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases. This unit is involved in the study of diabetes and obesity in the Pima Indian population of southwestern Arizona.

The typical duties may include clinical involvement in: studies of insulin resistance using a modified euglycemic clamp procedure; studies of insulin secretion; determination of body composition by underwater weighing; surgical fat biopsy procedures; percutaneous muscle biopsy techniques; thermogenesis studies using indirect calorimetric methods, studies of lipoprotein metabolism; and studies of the effects of treatment on diabetes mellitus and obesity.

In addition, some time may be spent in collaboration on *in vitro* projects relating to diabetes and obesity. These projects include morphologic, metabolic, and kinetic studies of adipocytes, muscle enzymology, and studies of lipoprotein composition and metabolism.

Qualifications

Candidates must be graduates of accredited medical (or osteopathic) schools and have satisfactorily completed an internship approved by the Council on Medical Education (or the American Osteopathic Association).


Generally, candidates must have completed 2 or 3 years of graduate medical training before entering on duty.

Foreign medical school graduates must have permanent certification by the Education Council for Foreign Medical Graduates or have passed the full examination of the National Board of Medical Examiners.

Resumes should be forwarded to:

Dr. Clifton Bogardus, M.D.
Chief, Clinical Diabetes & Nutrition Section
National Institutes of Health, NIADDK
4212 North 16th Street, Room 541
Phoenix, AZ 85016
Phone: (602) 263-1556

AN EQUAL OPPORTUNITY EMPLOYER



Having it all...only

Can be read either visually or
with Accu-Chek® II



The original dry-wipe strip






with Chemstrip bG[®]

The strip with unsurpassed service support programs:

- Patient education materials
- Staff training
- Nationwide Diabetes Supply Center Network
- Specialized sales force


Accuracy and reliability with maximum flexibility for "today, well lived."

CHEMSTRIP bG[®]



Available through Boehringer Mannheim Diabetes Supply Centers and most retail pharmacies. For more information, call 1-800-858-8072.

There is only one human insulin of recombinant DNA origin...



and it is identical to natural human insulin

From Lilly, a leader in diabetes care for six decades, there is now available the first and only insulin *not* derived from beef or pork pancreases—Humulin® (human insulin [recombinant DNA origin]).

In multicenter studies completed to date, Humulin was shown to be less immunogenic than mixed beef-pork or purified pork insulin. The clinical significance of these data has not yet been demonstrated.

Available in two forms: rapid-acting *Humulin® R* (regular human insulin [recombinant DNA origin], Injection) and intermediate-acting *Humulin® N* (NPH human insulin [recombinant DNA origin], Isophane Suspension).

Humulin®
human insulin
(recombinant DNA origin)

Lilly Leadership
IN DIABETES CARE

ANY CHANGE OF INSULIN SHOULD BE MADE CAUTIOUSLY AND ONLY UNDER MEDICAL SUPERVISION. CHANGES IN REFINEMENT, PURITY, STRENGTH, BRAND (MANUFACTURER), TYPE (REGULAR, NPH, LENTE®, ETC.), AND/OR METHOD OF MANUFACTURE (RECOMBINANT DNA VERSUS ANIMAL-SOURCE INSULIN) MAY RESULT IN THE NEED FOR A CHANGE IN DOSAGE.

For information on insulin delivery systems,
contact CPI: 1-(800)-CARDIAC.



Eli Lilly and Company
Indianapolis, Indiana 46285

500023

© 1984, ELI LILLY AND COMPANY